This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acute respiratory | 450 |
influenza virus | 353 |
respiratory syndrome | 340 |
respiratory tract | 311 |
severe acute | 280 |
virus infection | 215 |
respiratory syncytial | 190 |
syncytial virus | 185 |
serum samples | 175 |
respiratory viruses | 162 |
syndrome coronavirus | 147 |
infect dis | 144 |
cord uid | 141 |
doc id | 141 |
dis doi | 141 |
infectious diseases | 137 |
polymerase chain | 135 |
chain reaction | 132 |
immune response | 132 |
present study | 129 |
sars cov | 127 |
respiratory illness | 122 |
united states | 120 |
lower respiratory | 118 |
neutralizing antibody | 117 |
human coronavirus | 117 |
novel coronavirus | 116 |
influenza viruses | 114 |
respiratory virus | 111 |
influenza vaccine | 103 |
public health | 101 |
hong kong | 99 |
virus infections | 96 |
potential conflicts | 93 |
avian influenza | 92 |
pandemic influenza | 92 |
antibody responses | 90 |
symptom onset | 85 |
ebola virus | 85 |
viral load | 85 |
viral rna | 84 |
infected cells | 84 |
viral infection | 83 |
viral infections | 83 |
human metapneumovirus | 83 |
world health | 81 |
antibody response | 80 |
middle east | 79 |
respiratory disease | 78 |
health organization | 77 |
seasonal influenza | 76 |
coronavirus infection | 76 |
east respiratory | 76 |
respiratory infections | 75 |
convalescent plasma | 74 |
cov infection | 74 |
coronavirus disease | 72 |
immune responses | 72 |
described elsewhere | 72 |
statistically significant | 70 |
supplementary table | 69 |
young children | 69 |
risk factors | 68 |
antibody titers | 68 |
cell responses | 67 |
vg vd | 66 |
tract infections | 65 |
older adults | 65 |
upper respiratory | 65 |
sars coronavirus | 63 |
cell lines | 63 |
hospitalized patients | 60 |
bone marrow | 59 |
logistic regression | 59 |
time rt | 59 |
viral loads | 58 |
human bocavirus | 58 |
viral replication | 57 |
nucleic acid | 56 |
antibody titer | 56 |
severe disease | 55 |
coronavirus infections | 55 |
nai treatment | 55 |
clinical characteristics | 54 |
among patients | 53 |
age group | 53 |
human coronaviruses | 53 |
host cell | 52 |
performed using | 52 |
tract infection | 51 |
spike protein | 50 |
dengue virus | 50 |
tissue culture | 50 |
infectious disease | 49 |
neutralizing antibodies | 49 |
control group | 49 |
nipah virus | 49 |
vero cells | 49 |
study subjects | 49 |
disease severity | 48 |
influenza vaccines | 47 |
respiratory viral | 47 |
significantly higher | 47 |
immunocompromised patients | 47 |
influenza vaccination | 46 |
common cold | 46 |
tract disease | 46 |
relative humidity | 46 |
years old | 45 |
human rhinovirus | 45 |
acei arb | 45 |
chronic bronchitis | 44 |
acquired pneumonia | 44 |
may also | 44 |
new york | 44 |
previous studies | 44 |
supplementary materials | 44 |
acei arbs | 44 |
electron microscopy | 44 |
target cells | 44 |
disease control | 43 |
respiratory specimens | 43 |
test results | 43 |
systematic review | 43 |
tested positive | 43 |
healthy adults | 43 |
control patients | 42 |
respiratory symptoms | 42 |
airflow decline | 42 |
cell culture | 42 |
epithelial cells | 42 |
health care | 42 |
plasmodium falciparum | 41 |
clinical features | 41 |
determine whether | 40 |
time pcr | 40 |
severe respiratory | 40 |
confidence interval | 40 |
increased risk | 39 |
respiratory infection | 39 |
significant difference | 39 |
igg antibody | 39 |
within days | 39 |
clinical trials | 39 |
icmje form | 38 |
iu ml | 38 |
infdis jiaa | 38 |
jiaa sha | 38 |
linked immunosorbent | 38 |
hbov infection | 38 |
infected mdms | 37 |
parainfluenza virus | 37 |
amino acid | 37 |
immune system | 36 |
hcov infections | 35 |
like illness | 35 |
positive results | 35 |
live attenuated | 35 |
virus replication | 35 |
fold increase | 35 |
cd cd | 35 |
zika virus | 35 |
kawasaki disease | 35 |
financial support | 35 |
previously described | 34 |
samples collected | 34 |
viral shedding | 34 |
among children | 34 |
transplant recipients | 34 |
clinical specimens | 34 |
post symptom | 33 |
editors consider | 33 |
hmpv infection | 33 |
consider relevant | 33 |
human influenza | 33 |
immunosorbent assay | 33 |
data provided | 32 |
converting enzyme | 32 |
age groups | 32 |
pcr assay | 32 |
time reverse | 32 |
fri episodes | 32 |
pulmonary disease | 32 |
severe pneumonia | 32 |
rhinovirus infection | 32 |
patients infected | 32 |
lymph node | 31 |
vaccine development | 31 |
parainfluenza viruses | 31 |
west africa | 31 |
western blot | 31 |
odds ratio | 31 |
respiratory pathogens | 31 |
immunodeficiency virus | 31 |
herpes simplex | 30 |
sole responsibility | 30 |
proprotein convertases | 30 |
chronic obstructive | 30 |
nasopharyngeal swab | 30 |
median age | 30 |
informed consent | 30 |
serum sample | 30 |
animal models | 30 |
inactivated influenza | 30 |
pdm infection | 30 |
viral pathogens | 30 |
posted materials | 30 |
human immunodeficiency | 30 |
heart failure | 30 |
tract illness | 30 |
type i | 29 |
data suggest | 29 |
high risk | 29 |
genbank accession | 29 |
peripheral blood | 29 |
nucleocapsid protein | 29 |
intensive care | 29 |
infected patients | 29 |
cell cultures | 29 |
severe covid | 29 |
rna viruses | 29 |
obstructive pulmonary | 29 |
virus vaccine | 29 |
current study | 28 |
viral interference | 28 |
closely related | 28 |
reverse transcription | 28 |
infected individuals | 28 |
associated pneumonia | 28 |
cohort study | 28 |
cell line | 28 |
asymptomatic patients | 28 |
plasma samples | 28 |
associated coronavirus | 28 |
diseases online | 28 |
simulated sunlight | 28 |
significantly lower | 27 |
cell fusion | 27 |
viral sepsis | 27 |
flow cytometry | 27 |
described previously | 27 |
simplex virus | 27 |
human respiratory | 27 |
pcr assays | 27 |
endothelial cells | 27 |
study period | 27 |
vaccine virus | 27 |
liver disease | 27 |
bovine serum | 27 |
hospitalized children | 27 |
lymph nodes | 27 |
coronavirus hku | 27 |
antiviral therapy | 26 |
monoclonal antibody | 26 |
liver fibrosis | 26 |
sequence analysis | 26 |
binding domain | 26 |
bronchoalveolar lavage | 26 |
transcription polymerase | 26 |
positive samples | 26 |
infectious virus | 26 |
phylogenetic analysis | 26 |
nasal wash | 26 |
swab samples | 26 |
significant differences | 25 |
children aged | 25 |
community respiratory | 25 |
hcov infection | 25 |
necrosis factor | 25 |
tissue samples | 25 |
clinical samples | 25 |
regression model | 25 |
days post | 25 |
statistical significance | 25 |
healthcare workers | 25 |
results suggest | 25 |
study population | 25 |
west african | 24 |
samples obtained | 24 |
positive patients | 24 |
general population | 24 |
national institute | 24 |
viral detection | 24 |
insect cells | 24 |
respiratory distress | 24 |
applied biosystems | 24 |
homosexual men | 24 |
coronavirus spike | 24 |
significantly different | 24 |
placebo recipients | 24 |
inactivated vaccine | 23 |
pdm vaccine | 23 |
recent studies | 23 |
throat swabs | 23 |
receptor binding | 23 |
weight loss | 23 |
corresponding author | 23 |
virus disease | 23 |
testing positive | 23 |
genital herpes | 23 |
produced virus | 23 |
serum antibody | 23 |
specific cd | 23 |
respiratory illnesses | 23 |
tumor necrosis | 23 |
novel human | 23 |
ldi group | 23 |
single dose | 23 |
severe influenza | 23 |
high levels | 23 |
cytopathic effect | 23 |
situ hybridization | 23 |
pregnant ferrets | 22 |
population immunity | 22 |
pure viral | 22 |
challenge studies | 22 |
monoclonal antibodies | 22 |
clinical symptoms | 22 |
patients admitted | 22 |
blood samples | 22 |
reported conflicts | 22 |
less likely | 22 |
heart disease | 22 |
care unit | 22 |
institutional review | 22 |
room temperature | 22 |
mg kg | 22 |
care workers | 22 |
accession number | 22 |
subsequent fri | 22 |
coronavirus nl | 22 |
emergency department | 22 |
driven entry | 22 |
two groups | 22 |
specific antibodies | 22 |
probable sars | 22 |
time point | 22 |
pregnant women | 22 |
adverse events | 22 |
clinical signs | 22 |
human adenovirus | 22 |
stool specimens | 22 |
also tested | 21 |
soviet union | 21 |
culture medium | 21 |
children hospitalized | 21 |
common respiratory | 21 |
coronavirus oc | 21 |
exact test | 21 |
cell entry | 21 |
also found | 21 |
fri episode | 21 |
stem cell | 21 |
virus shedding | 21 |
genome sequence | 21 |
virus glycoprotein | 21 |
requiring hospitalization | 21 |
hi titers | 21 |
nucleotide sequences | 21 |
influenza pandemic | 21 |
human challenge | 21 |
rsv infection | 21 |
paired serum | 21 |
pcr products | 21 |
indirect immunofluorescence | 21 |
virus detection | 21 |
dendritic cells | 21 |
inflammatory response | 20 |
factors associated | 20 |
viral respiratory | 20 |
experimentally infected | 20 |
cytokine storm | 20 |
acute lower | 20 |
virus entry | 20 |
fetal bovine | 20 |
lung injury | 20 |
prospective study | 20 |
ferret model | 20 |
coronavirus associated | 20 |
time points | 20 |
statistical analysis | 20 |
like particles | 20 |
hcov non | 20 |
negative control | 20 |
important role | 20 |
study group | 20 |
novel hcov | 20 |
controlled trial | 20 |
virus type | 20 |
hemorrhagic fever | 20 |
united kingdom | 20 |
following infection | 20 |
aged years | 20 |
ivig lots | 20 |
oc infections | 20 |
patients hospitalized | 20 |
gof research | 20 |
proinflammatory cytokines | 20 |
hematopoietic cell | 20 |
lung tissue | 20 |
undue influence | 19 |
geometric mean | 19 |
detection rate | 19 |
previously reported | 19 |
viral antigen | 19 |
commercially available | 19 |
either hcov | 19 |
year period | 19 |
animal model | 19 |
clinical outcomes | 19 |
risk factor | 19 |
genomic load | 19 |
rural thailand | 19 |
cellular immune | 19 |
cell response | 19 |
acute phase | 19 |
sample size | 19 |
convalescent serum | 19 |
well tolerated | 19 |
sg hev | 19 |
serological assays | 19 |
two years | 19 |
infect humans | 19 |
infection among | 19 |
immunofluorescence assay | 19 |
similar results | 18 |
protective immunity | 18 |
mononuclear cells | 18 |
asymptomatic controls | 18 |
mortality rate | 18 |
clinical manifestations | 18 |
cell transplant | 18 |
hai antibody | 18 |
pneumonia requiring | 18 |
body weight | 18 |
higher levels | 18 |
nh infection | 18 |
adjuvanted vaccine | 18 |
group i | 18 |
clinical trial | 18 |
accession numbers | 18 |
van der | 18 |
mini kit | 18 |
severe cases | 18 |
two patients | 18 |
fisher exact | 18 |
asthma exacerbations | 18 |
also observed | 18 |
lrt infection | 18 |
review board | 18 |
nasopharyngeal aspirates | 18 |
respiratory diseases | 18 |
coronary arterial | 18 |
substance use | 18 |
highly pathogenic | 18 |
adjuvanted groups | 18 |
chest radiographs | 18 |
leishmania oligoc | 18 |
nk cells | 17 |
small intestine | 17 |
one patient | 17 |
pfsra peptide | 17 |
influenza infection | 17 |
cause severe | 17 |
cell transplantation | 17 |
fusion protein | 17 |
specimens obtained | 17 |
icu admission | 17 |
sars pneumonia | 17 |
infected animals | 17 |
total number | 17 |
technical assistance | 17 |
escherichia coli | 17 |
mg ml | 17 |
macro domain | 17 |
arb use | 17 |
severe illness | 17 |
host immune | 17 |
new human | 17 |
influenza surveillance | 17 |
lung disease | 17 |
findings suggest | 17 |
interval ci | 17 |
pcr results | 17 |
serum specimens | 17 |
confirmed cases | 17 |
specific antibody | 17 |
observational studies | 17 |
influenza activity | 17 |
influenza season | 17 |
innate immune | 17 |
control animals | 17 |
related infections | 17 |
sore throat | 17 |
buffered saline | 17 |
ng ml | 17 |
detection rates | 17 |
hiv infection | 17 |
patients without | 17 |
rabbit serum | 17 |
preseason hi | 17 |
antiviral activity | 17 |
research institute | 17 |
pfu dose | 17 |
viral species | 17 |
chest ct | 16 |
antibody levels | 16 |
angiotensin ii | 16 |
fluid samples | 16 |
virus subtype | 16 |
nucleocapsid proteins | 16 |
primary infection | 16 |
newly discovered | 16 |
ili cases | 16 |
pneumoniae infections | 16 |
hbov infections | 16 |
tract samples | 16 |
antibody avidity | 16 |
rhesus macaques | 16 |
mouse brain | 16 |
infections among | 16 |
igg antibodies | 16 |
mean age | 16 |
human transmission | 16 |
merozoite surface | 16 |
younger subjects | 16 |
proprotein convertase | 16 |
monkey kidney | 16 |
case definition | 16 |
adult patients | 16 |
human serum | 16 |
statistical analyses | 16 |
lymphocyte subsets | 16 |
phase serum | 16 |
bronchitis virus | 16 |
nonhuman primates | 16 |
research participation | 16 |
disease burden | 16 |
analyzed using | 16 |
hcov types | 16 |
congestive heart | 16 |
negative results | 16 |
nasopharyngeal swabs | 16 |
saudi arabia | 16 |
transmission dynamics | 16 |
infection control | 16 |
incidence rate | 16 |
high viral | 16 |
metapneumovirus infection | 16 |
transcriptase polymerase | 16 |
cells expressing | 16 |
airborne transmission | 16 |
seronegative children | 15 |
nucleotide sequence | 15 |
chemoattractant activity | 15 |
virus neutralization | 15 |
high prevalence | 15 |
specific igg | 15 |
disease virus | 15 |
clinical impact | 15 |
influenza epidemics | 15 |
mechanical ventilation | 15 |
fruit bats | 15 |
fatality rate | 15 |
viral etiology | 15 |
clinical course | 15 |
control subjects | 15 |
control measures | 15 |
well plates | 15 |
human parainfluenza | 15 |
national institutes | 15 |
vaccine candidates | 15 |
infected macrophages | 15 |
advanced fibrosis | 15 |
blood cells | 15 |
sequence identity | 15 |
virus titers | 15 |
systematic reviews | 15 |
studies reported | 15 |
human dna | 15 |
corticosteroid treatment | 15 |
blot analysis | 15 |
among hospitalized | 15 |
marrow transplant | 15 |
previous reports | 15 |
avian flua | 15 |
rhinovirus infections | 15 |
clinical research | 15 |
hiv antibody | 15 |
bacterial pathogens | 15 |
hospital admission | 15 |
proinflammatory response | 15 |
interquartile range | 15 |
low levels | 15 |
distress syndrome | 15 |
results indicate | 15 |
total rna | 15 |
peptide antibodies | 15 |
study year | 15 |
several studies | 15 |
hmpv pneumonia | 15 |
severe airflow | 15 |
per year | 15 |
vaccine candidate | 15 |
acid test | 15 |
unpublished data | 15 |
asymptomatic infections | 14 |
first days | 14 |
analysis revealed | 14 |
predicted fev | 14 |
symptomatic patients | 14 |
hospital mortality | 14 |
icu care | 14 |
human parvovirus | 14 |
recent study | 14 |
data set | 14 |
incidence rates | 14 |
phase i | 14 |
older children | 14 |
biopsy specimens | 14 |
ebov infection | 14 |
drug use | 14 |
hcov species | 14 |
also detected | 14 |
apache ii | 14 |
tcid ml | 14 |
older subjects | 14 |
sa kaeo | 14 |
pandemic potential | 14 |
native pfsra | 14 |
time polymerase | 14 |
treated patients | 14 |
may contribute | 14 |
laboratory diagnosis | 14 |
neutralization assay | 14 |
swab specimens | 14 |
specimen collection | 14 |
risk assessment | 14 |
subsequent infection | 14 |
african countries | 14 |
vaccine dose | 14 |
cryptosporidial oocysts | 14 |
virus may | 14 |
antigenically related | 14 |
hematopoietic stem | 14 |
natural history | 14 |
sample collection | 14 |
forward primer | 14 |
high genomic | 14 |
reverse primer | 14 |
total lymphocytes | 14 |
cleavage site | 14 |
rapid tests | 14 |
union research | 14 |
emerging infectious | 14 |
nasal aspirates | 14 |
specimens collected | 14 |
hypertensive covid | 14 |
tract specimens | 14 |
rna extraction | 14 |
hemagglutination inhibition | 14 |
control groups | 14 |
vgamma vdelta | 13 |
bd biosciences | 13 |
detection methods | 13 |
lrt detection | 13 |
confidence intervals | 13 |
respiratory samples | 13 |
year study | 13 |
erythrocyte invasion | 13 |
control study | 13 |
der hoek | 13 |
patients whose | 13 |
ace expression | 13 |
antiviral treatment | 13 |
frequent detection | 13 |
regression analysis | 13 |
ct values | 13 |
pneumonia patients | 13 |
patients presenting | 13 |
human infection | 13 |
cell monolayers | 13 |
zaire ebolavirus | 13 |
blood mononuclear | 13 |
cells specific | 13 |
surveillance system | 13 |
lung tissues | 13 |
ct value | 13 |
vaccine safety | 13 |
university hospital | 13 |
intersectoral collaboration | 13 |
virus isolated | 13 |
severe fever | 13 |
healthy individuals | 13 |
currently available | 13 |
suspected sars | 13 |
bat species | 13 |
previous study | 13 |
opioid use | 13 |
cell lysates | 13 |
type lectin | 13 |
african americans | 13 |
laboratory testing | 13 |
use disorder | 13 |
type ii | 13 |
amino acids | 13 |
chronic diarrhea | 13 |
personal protective | 13 |
currently circulating | 13 |
cd ratio | 13 |
adenovirus type | 13 |
diagnostic tests | 13 |
flua virus | 13 |
clinical outcome | 13 |
viral particles | 13 |
rhinovirus colds | 13 |
masstag pcr | 13 |
total antibody | 13 |
symptom score | 13 |
induced asthma | 13 |
throat swab | 13 |
human disease | 13 |
recently described | 13 |
pleural effusion | 13 |
humoral immune | 13 |
york city | 13 |
gene expression | 13 |
attenuated influenza | 13 |
adults aged | 13 |
infected monkeys | 13 |
medical center | 13 |
randomized controlled | 13 |
infections may | 13 |
virus vaccines | 13 |
infection due | 13 |
influenza transmission | 12 |
kaeo province | 12 |
aspirate samples | 12 |
higher proportion | 12 |
like receptors | 12 |
red deer | 12 |
antigenic relationships | 12 |
clinical disease | 12 |
envelope protein | 12 |
igm antibody | 12 |
newly identified | 12 |
signal peptide | 12 |
elderly persons | 12 |
jiz sha | 12 |
respiratory secretions | 12 |
naturally occurring | 12 |
virus detected | 12 |
asymptomatic control | 12 |
written informed | 12 |
research participants | 12 |
hepatitis virus | 12 |
pcr analysis | 12 |
total symptom | 12 |
young adults | 12 |
inject drugs | 12 |
visceral leishmaniasis | 12 |
hbov vp | 12 |
pcr amplification | 12 |
positive test | 12 |
viral protein | 12 |
disease onset | 12 |
acute infection | 12 |
mouse hepatitis | 12 |
first episode | 12 |
mouse model | 12 |
harm reduction | 12 |
protective equipment | 12 |
viral challenge | 12 |
hai titer | 12 |
adaptive immune | 12 |
diabetes mellitus | 12 |
sample sizes | 12 |
cytokine production | 12 |
red blood | 12 |
cov antibody | 12 |
care facilities | 12 |
epidemiological studies | 12 |
patient care | 12 |
infections occurred | 12 |
virus produced | 12 |
viral envelope | 12 |
fold dilutions | 12 |
tract symptoms | 12 |
future studies | 12 |
hct recipients | 12 |
thrombocytopenia syndrome | 12 |
viral antigens | 12 |
clinical studies | 12 |
associated illnesses | 12 |
without respiratory | 12 |
rousettus aegyptiacus | 12 |
horseradish peroxidase | 12 |
standard deviation | 12 |
significant increase | 12 |
human igg | 12 |
otitis media | 12 |
graphpad prism | 12 |
three patients | 12 |
pathogenic avian | 12 |
infdis jiz | 12 |
infectious bronchitis | 12 |
social distancing | 12 |
recently identified | 12 |
small number | 12 |
host defense | 12 |
culture supernatant | 12 |
confirmed covid | 12 |
respiratory failure | 12 |
positive control | 12 |
nasopharyngeal samples | 12 |
copy numbers | 12 |
spike glycoprotein | 12 |
democratic republic | 12 |
virus isolation | 12 |
tested negative | 12 |
negative test | 12 |
specimens tested | 12 |
complementary dna | 12 |
mrna expression | 12 |
sars cases | 12 |
north america | 12 |
even though | 12 |
multiplex pcr | 12 |
spanish influenza | 12 |
neutralization tests | 12 |
nested pcr | 12 |
age distribution | 12 |
dose cohort | 12 |
cov rna | 12 |
hi titer | 12 |
feral pigeons | 12 |
clinical data | 12 |
diagnostic testing | 12 |
pandemic vaccine | 12 |
highly conserved | 12 |
universal influenza | 12 |
vp vlps | 12 |
vector control | 12 |
york state | 12 |
serological tests | 12 |
viral entry | 12 |
confirmed sars | 12 |
per children | 12 |
calculated using | 12 |
guinea pigs | 12 |
potential cleavage | 12 |
serologic tests | 11 |
pg ml | 11 |
children years | 11 |
second dose | 11 |
infected mice | 11 |
mycoplasma pneumoniae | 11 |
pdm vaccination | 11 |
viral culture | 11 |
rectal swabs | 11 |
based study | 11 |
culture supernatants | 11 |
diffuse alveolar | 11 |
fisher scientific | 11 |
placebo group | 11 |
organ cultures | 11 |
study suggests | 11 |
predictive value | 11 |
paired samples | 11 |
cervical lymph | 11 |
neuraminidase inhibitor | 11 |
simulated saliva | 11 |
asymptomatic individuals | 11 |
alveolar damage | 11 |
close contact | 11 |
rapid test | 11 |
confirmed influenza | 11 |
copy number | 11 |
acute lung | 11 |
age range | 11 |
opioid epidemic | 11 |
causative agents | 11 |
dengue hemorrhagic | 11 |
positive specimens | 11 |
driven transduction | 11 |
trypanosoma cruzi | 11 |
cells infected | 11 |
vp vp | 11 |
illness onset | 11 |
entry driven | 11 |
regression models | 11 |
also showed | 11 |
sda virus | 11 |
infection human | 11 |
significant airflow | 11 |
paramyxovirus type | 11 |
real time | 11 |
data indicate | 11 |
specific primers | 11 |
samples tested | 11 |
vesicular stomatitis | 11 |
epithelial cell | 11 |
cleavage sites | 11 |
relationships among | 11 |
conserved regions | 11 |
become available | 11 |
community outbreak | 11 |
human cases | 11 |
another study | 11 |
cellular entry | 11 |
underlying diseases | 11 |
human population | 11 |
lymphoid tissue | 11 |
retrospective study | 11 |
apoptotic cells | 11 |
flua viruses | 11 |
disease caused | 11 |
bal fluid | 11 |
virus strains | 11 |
rbcv infection | 11 |
study protocol | 11 |
continued acei | 11 |
reactive antibodies | 11 |
viral pneumonia | 11 |
primed groups | 11 |
lung pathology | 11 |
coronavirus vaccine | 11 |
qiaamp viral | 11 |
expression levels | 11 |
staff members | 11 |
second season | 11 |
lymphocyte count | 11 |
reported previously | 11 |
hbov dna | 11 |
ns gene | 11 |
human embryonic | 11 |
zonula occludens | 11 |
sars patients | 11 |
flight patients | 11 |
antibody concentrations | 11 |
sera collected | 11 |
ii receptor | 11 |
may provide | 11 |
family cluster | 11 |
cov igg | 11 |
protein expression | 11 |
human rhinoviruses | 11 |
blood cell | 11 |
subacute phase | 11 |
may play | 11 |
human monoclonal | 11 |
quantitative real | 11 |
hospital stay | 11 |
significantly associated | 10 |
broad spectrum | 10 |
plasma treatment | 10 |
winter season | 10 |
randomized trial | 10 |
included patients | 10 |
signal intensity | 10 |
th day | 10 |
innate immunity | 10 |
sars outbreak | 10 |
initial episode | 10 |
first episodes | 10 |
vaccinia virus | 10 |
right axillary | 10 |
dendritic cell | 10 |
also shown | 10 |
first time | 10 |
ferrets infected | 10 |
reverse transcriptase | 10 |
reactive protein | 10 |
hendra virus | 10 |
serum albumin | 10 |
gastrointestinal symptoms | 10 |
fruit bat | 10 |
hiv seropositivity | 10 |
fatty liver | 10 |
virology laboratory | 10 |
ace receptor | 10 |
serially diluted | 10 |
nl infection | 10 |
vaccine effectiveness | 10 |
another virus | 10 |
intravenous immunoglobulin | 10 |
influenza pneumonia | 10 |
data collection | 10 |
sequence alignment | 10 |
serum antibodies | 10 |
like viruses | 10 |
nonpregnant ferrets | 10 |
white blood | 10 |
including influenza | 10 |
smudge cells | 10 |
absolute reduction | 10 |
hi responses | 10 |
first dose | 10 |
nl infections | 10 |
month period | 10 |
first infection | 10 |
convertase activity | 10 |
breda virus | 10 |
without asthma | 10 |
authors report | 10 |
following vaccination | 10 |
lung biopsy | 10 |
hospitalization rates | 10 |
molecular epidemiological | 10 |
also thank | 10 |
molecular diagnosis | 10 |
positive group | 10 |
infant mice | 10 |
winter months | 10 |
hrv species | 10 |
significantly reduced | 10 |
weeks later | 10 |
ethics committee | 10 |
bloody diarrhea | 10 |
within hours | 10 |
five days | 10 |
neutralization test | 10 |
adenovirus infection | 10 |
contact patients | 10 |
based surveillance | 10 |
illness group | 10 |
gel electrophoresis | 10 |
negative samples | 10 |
hcov detection | 10 |
months post | 10 |
ca i | 10 |
asymptomatic carriers | 10 |
overdose prevention | 10 |
kidney cells | 10 |
species transmission | 10 |
clr signaling | 10 |
severe lower | 10 |
detected among | 10 |
stomatitis virus | 10 |
eligibility criteria | 10 |
higher viral | 10 |
infection date | 10 |
parv dna | 10 |
pmnls lo | 10 |
trivalent inactivated | 10 |
vascular hyperpermeability | 10 |
neutralizing activity | 10 |
hadv genotype | 10 |
syndrome virus | 10 |
prospective cohort | 10 |
lo hpf | 10 |
bocavirus infection | 10 |
derived macrophages | 10 |
transmissible gastroenteritis | 10 |
fecal specimens | 10 |
among persons | 10 |
antigenic sin | 10 |
performance characteristics | 10 |
wash specimens | 10 |
study participants | 10 |
rna polymerase | 10 |
four days | 10 |
acute diarrhea | 10 |
surface protein | 10 |
neutralization assays | 10 |
using real | 10 |
oseltamivir treatment | 10 |
original antigenic | 10 |
symptom scores | 10 |
children less | 10 |
elderly patients | 10 |
treatment center | 10 |
challenge study | 10 |
injection site | 10 |
complete genome | 10 |
biosafety level | 10 |
positive children | 10 |
gnotobiotic calves | 10 |
reproduction number | 10 |
optical density | 10 |
hdpp tg | 10 |
infection may | 10 |
rural areas | 10 |
positive result | 10 |
among older | 10 |
nasal mucosa | 10 |
ccr mice | 10 |
possible cause | 10 |
left ventricular | 10 |
viral proteins | 10 |
two days | 10 |
data show | 10 |
significantly increased | 10 |
tract virus | 10 |
droplet precautions | 10 |
previously shown | 10 |
person transmission | 10 |
immunity passports | 10 |
significant association | 10 |
prevent infection | 10 |
viral cap | 10 |
military recruits | 10 |
may result | 10 |
acid sequence | 10 |
large number | 10 |
pneumonia associated | 10 |
cystic fibrosis | 10 |
sexual practices | 10 |
small sample | 10 |
genetic diversity | 10 |
leukocyte interferon | 10 |
rna concentration | 10 |
asthma exacerbation | 9 |
lymphocyte subset | 9 |
decay rate | 9 |
experimental rhinovirus | 9 |
rxxr motifs | 9 |
specific pcr | 9 |
per patient | 9 |
host disease | 9 |
specific pathogen | 9 |
initial infection | 9 |
increased levels | 9 |
febrile illness | 9 |
wt rsv | 9 |
ari cases | 9 |
fold rise | 9 |
dna copies | 9 |
fibroblast cells | 9 |
hrv infections | 9 |
binding site | 9 |
continuous variables | 9 |
year old | 9 |
new virus | 9 |
rs virus | 9 |
multivariate analysis | 9 |
ventricular cavity | 9 |
direct contact | 9 |
cov vaccine | 9 |
airway epithelial | 9 |
additional information | 9 |
human infections | 9 |
animals dying | 9 |
haemophilus influenzae | 9 |
mediated transduction | 9 |
infected vero | 9 |
animals infected | 9 |
sars virus | 9 |
dependent enhancement | 9 |
diarrhea associated | 9 |
antibody binding | 9 |
relative importance | 9 |
inoculated ic | 9 |
chemokine receptor | 9 |
lots produced | 9 |
clinical presentation | 9 |
infected pregnant | 9 |
determined using | 9 |
also used | 9 |
samples positive | 9 |
rank test | 9 |
southern china | 9 |
whole blood | 9 |
chronic respiratory | 9 |
rna mini | 9 |
uninfected cells | 9 |
pfsra antibodies | 9 |
prevention sites | 9 |
culture infectious | 9 |
control individuals | 9 |
preliminary report | 9 |
dna viruses | 9 |
molecular weight | 9 |
specific monoclonal | 9 |
cycle threshold | 9 |
will need | 9 |
uninfected individuals | 9 |
viruses may | 9 |
serological assay | 9 |
virus particles | 9 |
antibody production | 9 |
adverse responders | 9 |
dengue viruses | 9 |
propensity score | 9 |
newcastle disease | 9 |
immunity passport | 9 |
data support | 9 |
molecular epidemiology | 9 |
strain oc | 9 |
abi prism | 9 |
critically ill | 9 |
avidity indices | 9 |
virus transmission | 9 |
symptom severity | 9 |
electron microscopic | 9 |
organ culture | 9 |
limited data | 9 |
healthy donors | 9 |
included studies | 9 |
promoter region | 9 |
fever onset | 9 |
dna levels | 9 |
mers patients | 9 |
marburg virus | 9 |
clinical management | 9 |
influenza cases | 9 |
reactive antibody | 9 |
phylogenetic trees | 9 |
human macrophages | 9 |
multiorgan failure | 9 |
among young | 9 |
peripheral lymphocyte | 9 |
better understanding | 9 |
recent infection | 9 |
swab specimen | 9 |
pcr using | 9 |
peracetic acid | 9 |
aerosol transmission | 9 |
recombinant nucleocapsid | 9 |
air travel | 9 |
phylogenetic analyses | 9 |
mortality rates | 9 |
fever virus | 9 |
viruses detected | 9 |
normal range | 9 |
mk cells | 9 |
term care | 9 |
whose infection | 9 |
live virus | 9 |
quantitative polymerase | 9 |
synthetic peptides | 9 |
time course | 9 |
nervous system | 9 |
oxygen saturation | 9 |
may represent | 9 |
negative group | 9 |
respiratory coronavirus | 9 |
elderly adults | 9 |
infected ferrets | 9 |
elderly people | 9 |
sialic acid | 9 |
challenge trials | 9 |
infected children | 9 |
negative controls | 9 |
murine coronavirus | 9 |
nonhospitalized cases | 9 |
arterial diameter | 9 |
pneumonia cases | 9 |
without sars | 9 |
naturally acquired | 9 |
significant associations | 9 |
foam swabs | 9 |
salivary glands | 9 |
homologous virus | 9 |
among outpatients | 9 |
disease detection | 9 |
heart weight | 9 |
body temperature | 9 |
seasonal coronaviruses | 9 |
ill patients | 9 |
new coronavirus | 9 |
adjuvanted vaccines | 9 |
lung function | 9 |
taken together | 9 |
microscopic examination | 9 |
proteolytic processing | 9 |
much higher | 9 |
coronavirus pneumonia | 9 |
cold virus | 9 |
positive rate | 9 |
three times | 9 |
one year | 9 |
transport medium | 9 |
animals vaccinated | 9 |
different types | 9 |
way analysis | 9 |
family members | 9 |
patients received | 9 |
hyperimmune immunoglobulin | 9 |
frequently detected | 9 |
study design | 9 |
conducted using | 9 |
np aspirate | 9 |
horseshoe bats | 9 |
northern hemisphere | 9 |
tumor cell | 9 |
west nile | 9 |
prevention control | 9 |
university medical | 9 |
developing countries | 9 |
data available | 9 |
many countries | 8 |
symptomatic hiv | 8 |
plasma donations | 8 |
fully sequenced | 8 |
multivariable analysis | 8 |
vero cell | 8 |
genomic material | 8 |
antiviral drug | 8 |
gdd centers | 8 |
five years | 8 |
income countries | 8 |
relative risk | 8 |
hrsv long | 8 |
inflammatory cytokines | 8 |
two weeks | 8 |
use treatment | 8 |
controlled trials | 8 |
randomized clinical | 8 |
linked glycosylation | 8 |
lamina propria | 8 |
seasonal vaccines | 8 |
nai therapy | 8 |
folate receptor | 8 |
supplementary data | 8 |
considered statistically | 8 |
hai titers | 8 |
tecumseh study | 8 |
tissue tropism | 8 |
better understand | 8 |
immunocompetent patients | 8 |
genetic heterogeneity | 8 |
bronchial wall | 8 |
protective effect | 8 |
parasite culture | 8 |
adults hospitalized | 8 |
clinical setting | 8 |
lymphocyte counts | 8 |
pyrrolidine dithiocarbamate | 8 |
one week | 8 |
activator protein | 8 |
evaluated using | 8 |
pathological changes | 8 |
transplant patients | 8 |
clinical illness | 8 |
median number | 8 |
neuraminidase inhibitors | 8 |
effusion disease | 8 |
evidence suggests | 8 |
four months | 8 |
high incidence | 8 |
associated hospitalizations | 8 |
within west | 8 |
kg day | 8 |
repeated infections | 8 |
transduction efficiency | 8 |
discontinued acei | 8 |
without symptoms | 8 |
infection rates | 8 |
human leukocyte | 8 |
infectious agents | 8 |
dna polymerase | 8 |
nasal swabs | 8 |
membrane fusion | 8 |
fri incidence | 8 |
surveillance season | 8 |
wall thickenings | 8 |
swine influenza | 8 |
sftsv rnp | 8 |
antibiotic treatment | 8 |
readily detectable | 8 |
organ transplant | 8 |
epidemiological year | 8 |
nonadjuvanted groups | 8 |
patients showed | 8 |
sensitivity analysis | 8 |
infected cell | 8 |
pulmonary hypertension | 8 |
four patients | 8 |
messenger rna | 8 |
bacterial infections | 8 |
open reading | 8 |
nuclear entry | 8 |
higher rate | 8 |
working group | 8 |
rna extracted | 8 |
cell counts | 8 |
parv infection | 8 |
median period | 8 |
case reports | 8 |
autopsy samples | 8 |
measured using | 8 |
respiratory exacerbations | 8 |
induced myocarditis | 8 |
parasite invasion | 8 |
genomic loads | 8 |
posterior oropharyngeal | 8 |
inflammatory cells | 8 |
epidemiologically associated | 8 |
cc chemokine | 8 |
unknown whether | 8 |
tam receptor | 8 |
endemic coronaviruses | 8 |
tract illnesses | 8 |
nonhuman primate | 8 |
policy makers | 8 |
children younger | 8 |
western blotting | 8 |
pbs containing | 8 |
patients may | 8 |
studies used | 8 |
rsv season | 8 |
study provides | 8 |
cytokine responses | 8 |
lower airways | 8 |
coronavirus strain | 8 |
dengue infection | 8 |
clinical care | 8 |
mild symptoms | 8 |
study sites | 8 |
days following | 8 |
pigeon paramyxovirus | 8 |
infected study | 8 |
thank dr | 8 |
egyptian fruit | 8 |
analysis using | 8 |
genomic rna | 8 |
otherwise healthy | 8 |
spatial separation | 8 |
sg niv | 8 |
large numbers | 8 |
acid sequences | 8 |
protective efficacy | 8 |
asthmatic subjects | 8 |
inflammatory mediators | 8 |
test result | 8 |
case report | 8 |
sequence data | 8 |
nasopharyngeal aspirate | 8 |
showed similar | 8 |
categorical variables | 8 |
significant changes | 8 |
mean titers | 8 |
quasi species | 8 |
antibody tests | 8 |
serologic evidence | 8 |
high sensitivity | 8 |
serological testing | 8 |
human sars | 8 |
gastrointestinal tract | 8 |
least days | 8 |
regarding errors | 8 |
calf serum | 8 |
shed virus | 8 |
might also | 8 |
saliva specimens | 8 |
respiratory exacerbation | 8 |
reaction assays | 8 |
thermo fisher | 8 |
antiviral intervention | 8 |
humoral responses | 8 |
significant correlation | 8 |
global health | 8 |
villous epithelium | 8 |
early stages | 8 |
immune rabbit | 8 |
viral clearance | 8 |
next pandemic | 8 |
underwent bal | 8 |
virus load | 8 |
entry factors | 8 |
sentinel surveillance | 8 |
hi antibody | 8 |
advisory committee | 8 |
arb group | 8 |
oropharyngeal saliva | 8 |
seasonal distribution | 8 |
fluorescent antibody | 8 |
cold symptoms | 8 |
nordihydroguaiaretic acid | 8 |
transfected cells | 8 |
nab titers | 8 |
penton base | 8 |
hku specimens | 8 |
hospital admissions | 8 |
sirna depletion | 8 |
serum hai | 8 |
past years | 8 |
lesion scrapings | 8 |
ivanovsky institute | 8 |
like coronavirus | 8 |
syndrome identification | 8 |
cases occurred | 8 |
receiving interferon | 8 |
cell types | 8 |
cohort studies | 8 |
seven patients | 8 |
attack rates | 8 |
computed tomography | 8 |
right cervical | 8 |
viral preparations | 8 |
pediatric patients | 8 |
high frequency | 8 |
host cells | 8 |
lower limit | 8 |
care facility | 8 |
previously unknown | 8 |
observational study | 8 |
prior infection | 8 |
final concentration | 8 |
culture isolation | 8 |
may lead | 8 |
bal fluids | 8 |
hela cells | 8 |
cell surface | 8 |
vaccine groups | 8 |
expression system | 8 |
messages regarding | 8 |
central nervous | 8 |
infectious viral | 8 |
health research | 8 |
season serum | 8 |
mediated immunity | 8 |
see supplementary | 8 |
assay performance | 8 |
type iii | 8 |
among individuals | 8 |
human endothelial | 8 |
materials consist | 8 |
multiple comparisons | 8 |
urgently needed | 8 |
antibody assays | 8 |
reference laboratory | 8 |
productive cough | 8 |
independently associated | 8 |
protein processing | 8 |
medical records | 8 |
clade ii | 7 |
also occur | 7 |
study found | 7 |
days apart | 7 |
serum plasma | 7 |
demographic information | 7 |
eosinophil recruitment | 7 |
anal intercourse | 7 |
disease transmission | 7 |
encephalomyocarditis virus | 7 |
challenge virus | 7 |
became infected | 7 |
first week | 7 |
subset alteration | 7 |
attack rate | 7 |
significant effect | 7 |
ieip sites | 7 |
inflammatory responses | 7 |
brucei gambiense | 7 |
previous infection | 7 |
commissioned reviews | 7 |
mediated entry | 7 |
symptomatic children | 7 |
viral spike | 7 |
healthy controls | 7 |
may reflect | 7 |
may occur | 7 |
known hcovs | 7 |
mallard england | 7 |
especially among | 7 |
tract viruses | 7 |
obtained within | 7 |
i orf | 7 |
second vaccine | 7 |
probable cases | 7 |
cell expansion | 7 |
platelet counts | 7 |
african american | 7 |
serial dilutions | 7 |
gdd ieip | 7 |
reciprocal hi | 7 |
highest dilution | 7 |
hrv types | 7 |
mallard netherlands | 7 |
data analysis | 7 |
released merozoites | 7 |
infectious peritonitis | 7 |
immune sera | 7 |
cell immunity | 7 |
old age | 7 |
heart muscle | 7 |
will likely | 7 |
national center | 7 |
symptoms associated | 7 |
wild type | 7 |
prototype strains | 7 |
fecal samples | 7 |
asymptomatic infection | 7 |
postmortem examination | 7 |
surveillance sites | 7 |
maximum likelihood | 7 |
sera tested | 7 |
infdis jiy | 7 |
poorly understood | 7 |
healthy endemic | 7 |
dipeptidyl peptidase | 7 |
lower airway | 7 |
significant reduction | 7 |
stranded rna | 7 |
chinese horseshoe | 7 |
ii score | 7 |
modified eagle | 7 |
ct findings | 7 |
dependent manner | 7 |
viral transport | 7 |
viral pathogen | 7 |
host response | 7 |
reverse genetics | 7 |
study showed | 7 |
culture collection | 7 |
vaccine trials | 7 |
detectable virus | 7 |
antibody assay | 7 |
two studies | 7 |
high fever | 7 |
health insurance | 7 |
evd outbreaks | 7 |
kawasaki syndrome | 7 |
sensitivity analyses | 7 |
much lower | 7 |
single hcov | 7 |
rhinovirus serotypes | 7 |
gastroenteritis patients | 7 |
plaque reduction | 7 |
positively correlated | 7 |
response following | 7 |
virus groups | 7 |
birth cohort | 7 |
etiological agents | 7 |
whether hbov | 7 |
infections due | 7 |
circulating viruses | 7 |
case series | 7 |
serum specimen | 7 |
epidemiologic studies | 7 |
antiviral agents | 7 |
experimental animals | 7 |
taking acei | 7 |
allowed us | 7 |
group vs | 7 |
intercellular adhesion | 7 |
adhesion molecule | 7 |
nonstructural protein | 7 |
primary care | 7 |
differential diagnosis | 7 |
copies cells | 7 |
medium containing | 7 |
seropositive individuals | 7 |
lectins dc | 7 |
villous atrophy | 7 |
hsv cft | 7 |
mean value | 7 |
important cause | 7 |
fatality rates | 7 |
cardiac inflammation | 7 |
virus infectivity | 7 |
acute gvhd | 7 |
infections detected | 7 |
post hoc | 7 |
pandemic preparedness | 7 |
avian paramyxovirus | 7 |
highly specific | 7 |
reservoir hosts | 7 |
sas institute | 7 |
bal within | 7 |
safety concerns | 7 |
increased significantly | 7 |
autopsy tissue | 7 |
elderly individuals | 7 |
convalescent phase | 7 |
septic shock | 7 |
clinical isolate | 7 |
close contacts | 7 |
neutralizing titers | 7 |
attenuated rsv | 7 |
rhinovirus genotype | 7 |
assess whether | 7 |
pcr product | 7 |
influenza strains | 7 |
research group | 7 |
assessed using | 7 |
urgent need | 7 |
igm antibodies | 7 |
binding lectin | 7 |
like virus | 7 |
optimized cutoff | 7 |
human cov | 7 |
antigenic cross | 7 |
first case | 7 |
comparative analysis | 7 |
helper cell | 7 |
virus types | 7 |
australian children | 7 |
case studies | 7 |
jiy sha | 7 |
study team | 7 |
fecal viral | 7 |
neutralization antibody | 7 |
matched inactivated | 7 |
host range | 7 |
descriptive study | 7 |
ann arbor | 7 |
eagle medium | 7 |
laboratory tests | 7 |
subgroup analysis | 7 |
host species | 7 |
animal care | 7 |
cell count | 7 |
based vaccine | 7 |
recent report | 7 |
human subjects | 7 |
angiotensin system | 7 |
associated infections | 7 |
transcribed rna | 7 |
canine parvovirus | 7 |
functional receptor | 7 |
individuals born | 7 |
still unknown | 7 |
ethical concerns | 7 |
control samples | 7 |
laboratory animals | 7 |
pandemic virus | 7 |
group receiving | 7 |
clinical significance | 7 |
function tests | 7 |
novel influenza | 7 |
clades i | 7 |
using standard | 7 |
incentive payments | 7 |
virus lineages | 7 |
expanded vg | 7 |
direct patient | 7 |
causing viruses | 7 |
relatively small | 7 |
clinical isolates | 7 |
additional studies | 7 |
envelope glycoproteins | 7 |
virus isolate | 7 |
streptococcus pneumoniae | 7 |
control studies | 7 |
fetal calf | 7 |
malaria parasite | 7 |
first step | 7 |
information regarding | 7 |
pulmonary edema | 7 |
male sex | 7 |
multiplex real | 7 |
medical care | 7 |
identified studies | 7 |
potential pathogens | 7 |
advisory board | 7 |
pdm virus | 7 |
histologic examination | 7 |
complete protection | 7 |
animal coronaviruses | 7 |
differ significantly | 7 |
transmission routes | 7 |
signaling pathway | 7 |
may help | 7 |
assay panel | 7 |
plasma donors | 7 |
adverse responses | 7 |
suspension matrix | 7 |
gradient centrifugation | 7 |
aids study | 7 |
agarose gel | 7 |
beneficial effect | 7 |
goat anti | 7 |
leishmania dna | 7 |
time since | 7 |
vaccine efficacy | 7 |
primary analysis | 7 |
days old | 7 |
decision making | 7 |
since symptom | 7 |
wild birds | 7 |
previously healthy | 7 |
disease specialists | 7 |
early treatment | 7 |
group treated | 7 |
infection became | 7 |
treatment efficacy | 7 |
patients treated | 7 |
viral titers | 7 |
infected calves | 7 |
bacterial infection | 7 |
forming units | 7 |
based vaccines | 7 |
seven days | 7 |
four weeks | 7 |
multiple sclerosis | 7 |
particularly important | 7 |
urt testing | 7 |
pteropus spp | 7 |
severe pandemic | 7 |
clinical scores | 7 |
may affect | 7 |
quantified using | 7 |
significant change | 7 |
criminal justice | 7 |
seronegative participants | 7 |
suspected false | 7 |
exclusion criteria | 7 |
generated using | 7 |
free medium | 7 |
experimental infection | 7 |
malaria vaccine | 7 |
review boards | 7 |
gp subunit | 7 |
phylogenetic tree | 7 |
like receptor | 7 |
plasmids encoding | 7 |
asymptomatic cases | 7 |
asthma symptoms | 7 |
respiratory pathogen | 7 |
chronic gvhd | 7 |
remains unclear | 7 |
disease surveillance | 7 |
virus families | 7 |
solid organ | 7 |
highly effective | 7 |
copies ml | 7 |
coronavirus type | 7 |
receptor tyrosine | 7 |
mycobacterium tuberculosis | 7 |
results provide | 7 |
serum collected | 7 |
feline infectious | 7 |
house nested | 7 |
passport policies | 7 |
one study | 7 |
response groups | 7 |
original magnification | 7 |
body fluids | 7 |
protease cycle | 7 |
medically attended | 7 |
acute viral | 7 |
dutch clinical | 7 |
sars epidemic | 7 |
cardiovascular disease | 7 |
deer calves | 7 |
vascular dysfunction | 7 |
patients receiving | 7 |
watery diarrhea | 7 |
infection prevention | 7 |
odds ratios | 7 |
san francisco | 7 |
acute ili | 7 |
disease due | 7 |
molecular detection | 7 |
sepsis group | 7 |
infection rate | 7 |
bmt intake | 7 |
avian infectious | 7 |
upper airway | 7 |
two consecutive | 7 |
lower mortality | 7 |
endemic control | 7 |
detect sars | 7 |
biopsy samples | 7 |
patients requiring | 7 |
clinical findings | 7 |
tested using | 7 |
observed among | 7 |
became chronic | 7 |
surveillance program | 7 |
medical research | 7 |
study using | 6 |
subacute stage | 6 |
secretory pathway | 6 |
samples used | 6 |
effects model | 6 |
first study | 6 |
maintenance medium | 6 |
age category | 6 |
selection bias | 6 |
novel parvovirus | 6 |
titer rises | 6 |
atrophic villi | 6 |
hrsv infection | 6 |
antibody elisas | 6 |
frequently associated | 6 |
first reported | 6 |
protein cleavage | 6 |
studies indicate | 6 |
activated receptor | 6 |
virochip analysis | 6 |
prolonged viral | 6 |
produced antibodies | 6 |
previously published | 6 |
bronchial epithelial | 6 |
mdms infected | 6 |
rna isolation | 6 |
placebo recipient | 6 |
recombination events | 6 |
one health | 6 |
mouse igg | 6 |
group coronavirus | 6 |
us government | 6 |
etiological role | 6 |
viral extract | 6 |
per milliliter | 6 |
canine kidney | 6 |
clinical manifestation | 6 |
evd outbreak | 6 |
beneficial effects | 6 |
increased expression | 6 |
immune cells | 6 |
hsv isolation | 6 |
promoter regions | 6 |
conducted within | 6 |
inflammatory cytokine | 6 |
processed fragments | 6 |
early nai | 6 |
glycoprotein processing | 6 |
flocked swabs | 6 |
clinical associations | 6 |
longitudinal cohort | 6 |
asked whether | 6 |
cell percentage | 6 |
influenza illness | 6 |
clinical practice | 6 |
within africa | 6 |
stool samples | 6 |
dna sequences | 6 |
humidity levels | 6 |
human enterovirus | 6 |
genetic determinants | 6 |
health sector | 6 |
nonsepsis group | 6 |
urban areas | 6 |
healthy volunteers | 6 |
viral myocarditis | 6 |
pseudotypes bearing | 6 |
hrv infection | 6 |
coronavirus characterization | 6 |
frequently isolated | 6 |
recent years | 6 |
sequence diversity | 6 |
exact tests | 6 |
productive infection | 6 |
virus isolates | 6 |
immune activation | 6 |
lung transplantation | 6 |
demographic characteristics | 6 |
lethal disease | 6 |
positive nucleic | 6 |
median decrease | 6 |
oc infection | 6 |
results obtained | 6 |
acquired respiratory | 6 |
sputum specimens | 6 |
pathologic findings | 6 |
hmpv infections | 6 |
virus rna | 6 |
target cell | 6 |
using stata | 6 |
forced expiratory | 6 |
ifitm proteins | 6 |
antiviral activities | 6 |
lower levels | 6 |
nucleic acids | 6 |
supplementary tables | 6 |
among adults | 6 |
microbial pathogens | 6 |
hubei province | 6 |
extraction kit | 6 |
tiv recipients | 6 |
illness among | 6 |
mean number | 6 |
infectious dose | 6 |
data extraction | 6 |
dry ice | 6 |
barr virus | 6 |
virus hemagglutinin | 6 |
parv viral | 6 |
pediatric population | 6 |
cases per | 6 |
joining method | 6 |
rsv vaccines | 6 |
specific immune | 6 |
research ethics | 6 |
step rt | 6 |
comparative data | 6 |
health response | 6 |
rhesus monkey | 6 |
individual participant | 6 |
hcv oc | 6 |
nasal aspirate | 6 |
chronic lung | 6 |
laboratory data | 6 |
highly immunogenic | 6 |
expressing cells | 6 |
coronavirus isolates | 6 |
persons born | 6 |
rat coronavirus | 6 |
cytometry analysis | 6 |
inhibiting antibody | 6 |
specific virus | 6 |
produced matched | 6 |
relative cross | 6 |
polymerase gene | 6 |
collected days | 6 |
virus caused | 6 |
different viruses | 6 |
histopathological assessment | 6 |
potential targets | 6 |
matrix protein | 6 |
infdis jit | 6 |
zoonotic transmission | 6 |
individuals infected | 6 |
pandemic strain | 6 |
cell frequencies | 6 |
pfmsp antibodies | 6 |
viral coinfections | 6 |
potential confounders | 6 |
immunosorbent assays | 6 |
immunized animals | 6 |
sequence similarity | 6 |
viral stock | 6 |
adverse response | 6 |
samples using | 6 |
park memorial | 6 |
acute exacerbations | 6 |
also demonstrated | 6 |
viruslike particles | 6 |
emerging respiratory | 6 |
national influenza | 6 |
hospitalization rate | 6 |
may increase | 6 |
darby canine | 6 |
crypt epithelium | 6 |
bacterial culture | 6 |
mildly symptomatic | 6 |
purified using | 6 |
commonly used | 6 |
immunosuppressed patients | 6 |
antigen detection | 6 |
seasonal coronavirus | 6 |
clinical presentations | 6 |
large intestine | 6 |
standard curve | 6 |
human monocyte | 6 |
hct candidates | 6 |
interferon treatment | 6 |
cells may | 6 |
symptomatic infection | 6 |
virus loads | 6 |
niv infection | 6 |
enzyme inhibitor | 6 |
cov pneumonia | 6 |
cd ligand | 6 |
positive pairs | 6 |
recovered individuals | 6 |
adult population | 6 |
pooled np | 6 |
much less | 6 |
exposure variable | 6 |
extracted dna | 6 |
cd lymphocyte | 6 |
tissue infections | 6 |
first hrv | 6 |
rectal hsv | 6 |
reach statistical | 6 |
ml range | 6 |
trend towards | 6 |
total igg | 6 |
sftsv genome | 6 |
independent risk | 6 |
poorly defined | 6 |
dna extraction | 6 |
acute stage | 6 |
life technologies | 6 |
laboratory findings | 6 |
pdm vaccines | 6 |
illnesses associated | 6 |
viral diagnosis | 6 |
common colds | 6 |
modified vaccinia | 6 |
low risk | 6 |
inflammatory changes | 6 |
associated acute | 6 |
positive cells | 6 |
newly emerging | 6 |
memorial institute | 6 |
hadv infections | 6 |
east africa | 6 |
potential benefits | 6 |
organ dysfunction | 6 |
swab sample | 6 |
people living | 6 |
inoculated animals | 6 |
atypical bacteria | 6 |
children without | 6 |
may cause | 6 |
tim proteins | 6 |
cell numbers | 6 |
rapid diagnosis | 6 |
microneutralization titer | 6 |
polyclonal antibody | 6 |
significantly greater | 6 |
six patients | 6 |
different age | 6 |
complete replication | 6 |
microneutralization assay | 6 |
rneasy mini | 6 |
cynomolgus macaques | 6 |
sample pairs | 6 |
brain tissue | 6 |
direct benefit | 6 |
patients positive | 6 |
pcr kit | 6 |
high rate | 6 |
blood tests | 6 |
medical conditions | 6 |
also examined | 6 |
motifs located | 6 |
patients presented | 6 |
type culture | 6 |
luciferase activity | 6 |
secondary antibody | 6 |
higher titers | 6 |
antibody testing | 6 |
previously undescribed | 6 |
several limitations | 6 |
specific immunity | 6 |
independent experiments | 6 |
seropositive children | 6 |
many years | 6 |
days later | 6 |
control specimens | 6 |
american type | 6 |
cellular factors | 6 |
sars infection | 6 |
study may | 6 |
left coronary | 6 |
also reported | 6 |
respiratory tracts | 6 |
tm domain | 6 |
crude extract | 6 |
excellent technical | 6 |
bal cell | 6 |
four human | 6 |
hi response | 6 |
unclear whether | 6 |
end points | 6 |
within day | 6 |
virus interference | 6 |
threshold cycle | 6 |
primary human | 6 |
fold higher | 6 |
transcription pcr | 6 |
hospitalized cases | 6 |
separate experiments | 6 |
prospectively collected | 6 |
entry mediated | 6 |
expression plasmids | 6 |
immune status | 6 |
nearly identical | 6 |
three days | 6 |
hev quasispecies | 6 |
human airway | 6 |
cell monolayer | 6 |
animal studies | 6 |
convalescent sera | 6 |
ili incidence | 6 |
less frequently | 6 |
renal function | 6 |
one hundred | 6 |
significantly decreased | 6 |
samples showed | 6 |
adjusted odds | 6 |
infection incidence | 6 |
clinical progression | 6 |
dromedary camels | 6 |
children admitted | 6 |
inhibition cutoff | 6 |
subjectively unreasonable | 6 |
sodium dodecyl | 6 |
fluv infection | 6 |
zika pandemic | 6 |
disease prevention | 6 |
expiratory volume | 6 |
nasal washes | 6 |
reproductive number | 6 |
associated sars | 6 |
nasopharyngeal specimens | 6 |
molecular marker | 6 |
hcov subtypes | 6 |
blood donors | 6 |
participant data | 6 |
strand rna | 6 |
reaction analysis | 6 |
right ventricular | 6 |
studies using | 6 |
acid substitutions | 6 |
natural killer | 6 |
surveillance network | 6 |
rabbit coronavirus | 6 |
wash samples | 6 |
available data | 6 |
median time | 6 |
previously identified | 6 |
inhibitory activity | 6 |
clinical virus | 6 |
routine laboratory | 6 |
mediated cell | 6 |
capture probe | 6 |
nasal secretions | 6 |
among different | 6 |
aged children | 6 |
analysis showed | 6 |
hospital discharge | 6 |
virus ankara | 6 |
patients developed | 6 |
hcov ili | 6 |
us military | 6 |
acid extraction | 6 |
whitney test | 6 |
different virus | 6 |
transmission within | 6 |
antigenic drift | 6 |
pathogenic human | 6 |
infected volunteers | 6 |
discovered coronavirus | 6 |
broad range | 6 |
mucin domain | 6 |
nonadjuvanted vaccine | 6 |
admission rates | 6 |
virus envelope | 6 |
commercial enzyme | 6 |
bal specimens | 6 |
investigated whether | 6 |
rsv disease | 6 |
laboratory confirmation | 6 |
point titer | 6 |
radiological findings | 6 |
african clades | 6 |
first months | 6 |
cov spike | 6 |
paired sera | 6 |
vaccination strategies | 6 |
patients provided | 6 |
oropharyngeal swabs | 6 |
acute hepatitis | 6 |
primary cause | 6 |
denv infection | 6 |
log tcid | 6 |
presenting cells | 6 |
antibody specific | 6 |
diseases society | 6 |
control vbds | 6 |
randomised controlled | 6 |
human rsv | 6 |
clinical suspicion | 6 |
rsv vaccine | 6 |
lrt testing | 6 |
combination therapy | 6 |
potential role | 6 |
significant risk | 6 |
three studies | 6 |
serine protease | 6 |
significant proportion | 6 |
substantial number | 6 |
vp proteins | 6 |
viral suppression | 6 |
molecular evolutionary | 6 |
medical attention | 6 |
using graphpad | 6 |
control calves | 6 |
evolutionary genetics | 6 |
novel viruses | 6 |
rsv surveillance | 6 |
advanced liver | 6 |
cells via | 6 |
genetics analysis | 6 |
roswell park | 6 |
coinfections occurred | 6 |
grabbing nonintegrin | 6 |
tracheal organ | 6 |
embryonic lung | 6 |
aspartate aminotransferase | 6 |
serological evidence | 6 |
limited number | 6 |
united nations | 6 |
small numbers | 6 |
finding suggests | 6 |
major cause | 6 |
inhibitory effect | 6 |
task force | 6 |
short period | 6 |
incubation period | 6 |
determined whether | 6 |
green monkey | 6 |
research center | 6 |
normal activities | 6 |
recently reported | 6 |
false negative | 6 |
mer expression | 6 |
positive pcr | 6 |
virus inoculation | 6 |
surveillance systems | 6 |
ebov entry | 6 |
immunization practices | 6 |
fatal cases | 6 |
highest among | 6 |
lung transcriptome | 6 |
falciparum merozoite | 6 |
identified virus | 6 |
envelope glycoprotein | 6 |
primer pairs | 6 |
viruses identified | 6 |
radiological features | 6 |
pcr testing | 6 |
propensity scores | 6 |
chikungunya virus | 6 |
health protection | 6 |
early phase | 6 |
us population | 6 |
primers used | 6 |
jit sha | 6 |
serologic testing | 6 |
six months | 6 |
ct scans | 6 |
reduced ebov | 6 |
hcp characteristics | 6 |
rural bangladesh | 6 |
broadly cross | 6 |
grant number | 6 |
cardiovascular risk | 6 |
adaptive immunity | 6 |
influenza pandemics | 6 |
driven cell | 6 |
nile virus | 6 |
may well | 6 |
relatively short | 6 |
protocol eligibility | 6 |
seroepidemiologic studies | 6 |
falciparum erythrocyte | 6 |
throughout china | 6 |
clinical diagnosis | 6 |
polyproline region | 6 |
angiotensin converting | 6 |
lung transplant | 6 |
based multiplex | 6 |
antiviral drugs | 6 |
nosocomial transmission | 6 |
serious adverse | 6 |
prior studies | 6 |
randomized trials | 6 |
full genomes | 6 |
discovered human | 6 |
becton dickinson | 5 |
allogeneic hematopoietic | 5 |
infected human | 5 |
microarray analysis | 5 |
underlying conditions | 5 |
treated mice | 5 |
exceptionally potent | 5 |
multiple sequence | 5 |
study clinical | 5 |
mild clinical | 5 |
excluded patients | 5 |
acute exacerbation | 5 |
comparably inhibited | 5 |
invasive pneumococcal | 5 |
negative binomial | 5 |
milder disease | 5 |
length genome | 5 |
using nasopharyngeal | 5 |
mf adjuvant | 5 |
high proportion | 5 |
blastic cells | 5 |
old mice | 5 |
within months | 5 |
model included | 5 |
blood sample | 5 |
class ii | 5 |
aged patients | 5 |
marrow transplantation | 5 |
illness groups | 5 |
human pathogens | 5 |
oxygen therapy | 5 |
mask use | 5 |
iii orf | 5 |
lymphocytic leukemia | 5 |
genome sequencing | 5 |
blood culture | 5 |
los among | 5 |
vaccine licensure | 5 |
strongly associated | 5 |
ethically acceptable | 5 |
different viral | 5 |
poct devices | 5 |
study also | 5 |
multiplex assay | 5 |
gene sequences | 5 |
cells transfected | 5 |
institute medium | 5 |
previous findings | 5 |
strongly suggest | 5 |
borne diseases | 5 |
health regulations | 5 |
associated encephalopathy | 5 |
highly sensitive | 5 |
nab responses | 5 |
vital capacity | 5 |
clinically relevant | 5 |
receptor blocker | 5 |
military training | 5 |
igm rapid | 5 |
primers specific | 5 |
plasma collected | 5 |
alveolar macrophages | 5 |
igg igm | 5 |
wallis test | 5 |
single representative | 5 |
born prior | 5 |
increased likelihood | 5 |
organ samples | 5 |
icu stay | 5 |
illness associated | 5 |
serotype strain | 5 |
significant number | 5 |
among people | 5 |
nonsynonymous mutations | 5 |
supplemental oxygen | 5 |
wantai sars | 5 |
nonalcoholic fatty | 5 |
environmental contamination | 5 |
mortality among | 5 |
ml penicillin | 5 |
viral uptake | 5 |
cell factors | 5 |
university school | 5 |
outcomes among | 5 |
laboratory animal | 5 |
case management | 5 |
newly described | 5 |
production coincided | 5 |
gastrointestinal viruses | 5 |
results showed | 5 |
positively associated | 5 |
specific primer | 5 |
mechanisms underlying | 5 |
comparative studies | 5 |
data also | 5 |
neutralizing human | 5 |
ordinal hi | 5 |
falciparum surface | 5 |
coronary artery | 5 |
increased viral | 5 |
significantly upregulated | 5 |
pcr tests | 5 |
investigate whether | 5 |
atypical pneumonia | 5 |
statistical computing | 5 |
environmental conditions | 5 |
including ppmv | 5 |
china clinical | 5 |
burden estimates | 5 |
vitro studies | 5 |
th cytokine | 5 |
low level | 5 |
including sars | 5 |
often present | 5 |
luciferase activities | 5 |
antiviral effect | 5 |
acute asthma | 5 |
significant levels | 5 |
mn responses | 5 |
high rates | 5 |
detected hcov | 5 |
dwelling older | 5 |
data presented | 5 |
later confirmed | 5 |
earlier studies | 5 |
rectal biopsies | 5 |
monovalent inactivated | 5 |
linked immunospot | 5 |
pulmonary fibrosis | 5 |
positive multiple | 5 |
hospitalizations among | 5 |
african green | 5 |
opportunistic infections | 5 |
pandemic threat | 5 |
representative experiment | 5 |
whereas others | 5 |
pregnant ferret | 5 |
different respiratory | 5 |
cell contact | 5 |
family coronaviridae | 5 |
repeated annual | 5 |
saharan africa | 5 |
endothelial cell | 5 |
airborne precautions | 5 |
human erythrocytes | 5 |
earlier reports | 5 |
cysteine proteases | 5 |
phosphotungstic acid | 5 |
animal covs | 5 |
subgroup genomes | 5 |
many cases | 5 |